Web Stats Provided By Google Analytics

Thursday, November 30, 2017

Leerink Swann Reiterates "Buy" Rating for CymaBay Therapeutics

... the biopharmaceutical company's stock worth $100,000 after acquiring an additional 140 shares in the last quarter. Ardsley Advisory Partners boosted its stake in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now ...
http://ift.tt/2Bnn8zB

No comments:

Post a Comment

Popular Ardsley Roundup Posts